Re: Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Original languageEnglish (US)
    Pages (from-to)413-414
    Number of pages2
    JournalJournal of Urology
    Volume188
    Issue number2
    DOIs
    StatePublished - Aug 2012

    ASJC Scopus subject areas

    • Urology

    Cite this